A randomized controlled trial of mindfulness-based stress reduction (MBSR) in Chilean health workers

Mindfulness based stress reduction (MBSR) for psychological distress reduction in Chilean health workers: a randomized controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN12039804

Enrollment

150

Registered

2018-03-26

Start date

2018-03-20

Completion date

Unknown

Last updated

2022-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychological distress/occupational stress (i.e. quality of life, perceived stress, burnout, depressive symptoms). Mental and Behavioural Disorders Stress

Interventions

Participants in the trial are full-time health workers employed by the UC Christus Health Network working at the "UC Christus Marcoleta Health Complex" in Santiago, Chile. All health workers will be i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Health worker at UC Christus Marcoleta Health Complex 2. Has direct patient contact 3. Gives consent

Exclusion criteria

Exclusion criteria: 1. Working under a fixed-term contract 2. Not in direct contact with patient 3. Reporting severe depression symptoms (OQ-45 score >= 47) 4. Reporting suicidal ideation (OQ-45 item 8 "almost always") 5. Reporting problematic alcohol consumption (OQ-45 item 11 "almost always") 6. Not available to attend to all 8 sessions of an MBSR course/Stress Education and Self-Management Workshop

Design outcomes

Primary

Measure	Time frame
Current primary outcome measure as of 20/07/2020: 1. Psychological distress measured using the 12-item General Health Questionnaire (GHQ-12) 2. Perceived stress, as measured by the Perceives Stress Scale (PSS) 3. Symptoms of distress (SD), interpersonal relations (IR) and social role (SR) performance, as measured by the Outcome Questionnaire (OQ 45) All primary outcomes will be measured at baseline (T0), at week 8 immediately after the intervention (T1) and 6 months after baseline (T2) in all participants. Previous primary outcome measure: 1. Psychological distress measured using the 12-item General Health Questionnaire (GHQ-12) 2. Burnout, as measured by the Maslach Burnout Inventory (MBI) 3. Perceived stress, as measured by the Perceives Stress Scale (PSS) 4. Symptoms of distress (SD), interpersonal relations (IR) and social role (SR) performance, as measured by the Outcome Questionnaire (OQ 45) 5. Circadian excursions of salivary cortisol concentrations, as measured by LC/MS-MS. Salivary samples for cortisol measurements will be collected at 3 time points/day (at awakening, 30 min after awakening and at bedtime or around 10 pm) prior to intervention (1 day = 3 measurements/person) and post intervention (1 day = 3 measurements/ person). Saliva samples will be collected using a Salivette Cortisol (Sarsted, Germany) device. All primary outcomes except cortisol concentration will be measured at baseline (T0), at week 8 immediately after the intervention (T1) and 6 months after baseline (T2) in all participants. Cortisol concentration will only be measured at T0 and T1 and only in participants receiving MBSR or passive controls Updated 10/08/2018: Cortisol concentration will only be measured at T0 and T1	—

Measure

Time frame

Current primary outcome measure as of 20/07/2020: 1. Psychological distress measured using the 12-item General Health Questionnaire (GHQ-12) 2. Perceived stress, as measured by the Perceives Stress Scale (PSS) 3. Symptoms of distress (SD), interpersonal relations (IR) and social role (SR) performance, as measured by the Outcome Questionnaire (OQ 45) All primary outcomes will be measured at baseline (T0), at week 8 immediately after the intervention (T1) and 6 months after baseline (T2) in all participants. Previous primary outcome measure: 1. Psychological distress measured using the 12-item General Health Questionnaire (GHQ-12) 2. Burnout, as measured by the Maslach Burnout Inventory (MBI) 3. Perceived stress, as measured by the Perceives Stress Scale (PSS) 4. Symptoms of distress (SD), interpersonal relations (IR) and social role (SR) performance, as measured by the Outcome Questionnaire (OQ 45) 5. Circadian excursions of salivary cortisol concentrations, as measured by LC/MS-MS. Salivary samples for cortisol measurements will be collected at 3 time points/day (at awakening, 30 min after awakening and at bedtime or around 10 pm) prior to intervention (1 day = 3 measurements/person) and post intervention (1 day = 3 measurements/ person). Saliva samples will be collected using a Salivette Cortisol (Sarsted, Germany) device. All primary outcomes except cortisol concentration will be measured at baseline (T0), at week 8 immediately after the intervention (T1) and 6 months after baseline (T2) in all participants. Cortisol concentration will only be measured at T0 and T1 and only in participants receiving MBSR or passive controls Updated 10/08/2018: Cortisol concentration will only be measured at T0 and T1

—

Secondary

Measure	Time frame
Current secondary outcome measures as of 20/07/2020: 1. Job satisfaction, as measured by the Job Satisfaction Scale (JSS) 2. Number of sick leaves in the previous three months 3. Mindfulness skills, as measured by the Five Facet Mindfulness Questionnaire (FFMQ) 4. Other quality-of-life indicators (e.g. comorbidity, sleep quality) 5. Circadian excursions of salivary cortisol concentrations, as measured by LC/MS-MS. Salivary samples for cortisol measurements will be collected at 3 time points/day (at awakening, 30 min after awakening and at bedtime or around 10 pm) prior to intervention (1 day = 3 measurements/person) and post intervention (1 day = 3 measurements/ person). Saliva samples will be collected using a Salivette Cortisol (Sarsted, Germany) device. All secondary outcomes will be measured at T0, T1, and T2 in all participants, bar cortisol concentration, which will only be measured at T0 and T1. Previous secondary outcome measures: 1. Job satisfaction, as measured by the Job Satisfaction Scale (JSS) 2. Number of sick leaves in the previous three months 3. Mindfulness skills, as measured by the Five Facet Mindfulness Questionnaire (FFMQ) 4. Other quality-of-life indicators (e.g. comorbidity, sleep quality) All secondary outcomes will be measured at T0, T1, and T2 in all participants.	—

Measure

Time frame

Current secondary outcome measures as of 20/07/2020: 1. Job satisfaction, as measured by the Job Satisfaction Scale (JSS) 2. Number of sick leaves in the previous three months 3. Mindfulness skills, as measured by the Five Facet Mindfulness Questionnaire (FFMQ) 4. Other quality-of-life indicators (e.g. comorbidity, sleep quality) 5. Circadian excursions of salivary cortisol concentrations, as measured by LC/MS-MS. Salivary samples for cortisol measurements will be collected at 3 time points/day (at awakening, 30 min after awakening and at bedtime or around 10 pm) prior to intervention (1 day = 3 measurements/person) and post intervention (1 day = 3 measurements/ person). Saliva samples will be collected using a Salivette Cortisol (Sarsted, Germany) device. All secondary outcomes will be measured at T0, T1, and T2 in all participants, bar cortisol concentration, which will only be measured at T0 and T1. Previous secondary outcome measures: 1. Job satisfaction, as measured by the Job Satisfaction Scale (JSS) 2. Number of sick leaves in the previous three months 3. Mindfulness skills, as measured by the Five Facet Mindfulness Questionnaire (FFMQ) 4. Other quality-of-life indicators (e.g. comorbidity, sleep quality) All secondary outcomes will be measured at T0, T1, and T2 in all participants.

—

Countries

Chile

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 25, 2026